Fibrocell Science Inc  

(Public, NYSEMKT:FCSC)   Watch this stock  
Find more results for Kirk K. Smith
+0.09 (2.74%)
Jul 24 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 3.25 - 3.38
52 week 2.70 - 6.30
Open 3.30
Vol / Avg. 88,333.00/223,564.00
Mkt cap 138.10M
P/E     -
Div/yield     -
EPS -1.22
Shares 40.86M
Beta -0.26
Inst. own 66%
Jun 20, 2014
Fibrocell Science Inc Annual Shareholders Meeting
Jun 5, 2014
Fibrocell Science Inc at Jefferies Global Healthcare Conference
May 19, 2014
Q1 2014 Fibrocell Science Inc Earnings Conference Call
May 19, 2014
Q1 2014 Fibrocell Science Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -30454.35% -15777.00%
Operating margin -23913.04% -15251.50%
EBITD margin - -14801.50%
Return on average assets -85.52% -57.57%
Return on average equity -123.79% -85.45%
Employees 58 -
CDP Score - -


405 Eagleview Boulevard
EXTON, PA 19341
United States - Map
+1-484-7136000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Fibrocell Science, Inc. is an aesthetic and therapeutic development stage biotechnology company focused on developing skin and tissue rejuvenation products. The Company�s clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient�s own, or autologous, fibroblast cells produced by its Fibrocell process. The Company�s clinical development programs encompass both aesthetic and therapeutic indications. Through December 31, 2011, the Company has been primarily engaged in developing its initial product technology. Its lead product, LAVIV (United States adopted name, or USAN, is azficel-T), is the personalized aesthetic cell therapy approved by the Food and Drug Administration (FDA). LAVIV offers patients their own living fibroblast cells in a personalized therapy designed to improve the appearance of wrinkles.

Officers and directors

David M. Pernock Chairman of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Gregory L. Weaver Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
Robert Sheroff Vice President - Technical Operations
Bio & Compensation  - Reuters
Kelvin Moore Lead Independent Director
Age: 64
Bio & Compensation  - Reuters
Julian P. Kirk Director
Age: 39
Bio & Compensation  - Reuters
Marcus Smith Director
Age: 58
Bio & Compensation  - Reuters
Marc B. Mazur Independent Director
Age: 54
Bio & Compensation  - Reuters
Christine Thompson St.Clare Independent Director
Age: 62
Bio & Compensation  - Reuters